Raymond James reissued their outperform rating on shares of Knight Therapeutics (TSE:GUD) in a research report report published on Wednesday morning. The brokerage currently has a C$10.25 price objective on the stock.
Separately, Bloom Burton reissued an accumulate rating on shares of Knight Therapeutics in a report on Friday, November 9th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Knight Therapeutics currently has a consensus rating of Buy and a consensus price target of C$10.06.
Shares of Knight Therapeutics stock opened at C$8.16 on Wednesday. Knight Therapeutics has a 12 month low of C$7.38 and a 12 month high of C$8.81.
About Knight Therapeutics
Knight Therapeutics Inc operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Impavido, an alkyllysophospholipid analogue drug for visceral and cutaneous Leishmaniasis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; and Flat Tummy Tea, a herbal detox tea.
Further Reading: Hedge Funds
Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.